Anika Therapeutics, Inc. (NASDAQ:ANIK) Shares Sold by Capital Management Corp VA

Capital Management Corp VA trimmed its holdings in Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report) by 11.6% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 290,350 shares of the biotechnology company's stock after selling 38,270 shares during the period. Capital Management Corp VA owned about 1.99% of Anika Therapeutics worth $7,172,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also made changes to their positions in ANIK. Boston Partners bought a new position in shares of Anika Therapeutics during the first quarter valued at approximately $733,000. State Board of Administration of Florida Retirement System purchased a new stake in shares of Anika Therapeutics in the first quarter valued at approximately $198,000. Meros Investment Management LP boosted its holdings in shares of Anika Therapeutics by 25.0% in the second quarter. Meros Investment Management LP now owns 212,714 shares of the biotechnology company's stock valued at $5,388,000 after purchasing an additional 42,587 shares during the period. Riverwater Partners LLC boosted its holdings in shares of Anika Therapeutics by 539.1% in the third quarter. Riverwater Partners LLC now owns 101,996 shares of the biotechnology company's stock valued at $2,552,000 after purchasing an additional 86,037 shares during the period. Finally, Stonepine Capital Management LLC lifted its holdings in Anika Therapeutics by 171.4% during the second quarter. Stonepine Capital Management LLC now owns 165,397 shares of the biotechnology company's stock worth $4,190,000 after buying an additional 104,448 shares during the period. 91.53% of the stock is currently owned by hedge funds and other institutional investors.

Anika Therapeutics Trading Down 4.5 %

Shares of ANIK stock traded down $0.77 during trading hours on Tuesday, reaching $16.30. 222,691 shares of the company's stock were exchanged, compared to its average volume of 66,414. The stock's 50 day moving average is $24.45 and its 200-day moving average is $25.58. The company has a market cap of $241.24 million, a price-to-earnings ratio of -2.57 and a beta of 0.86. Anika Therapeutics, Inc. has a fifty-two week low of $16.00 and a fifty-two week high of $29.11.

Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.23 by ($0.24). The business had revenue of $41.92 million for the quarter, compared to analyst estimates of $39.90 million. Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%. During the same period in the previous year, the company posted ($0.06) earnings per share. Equities analysts anticipate that Anika Therapeutics, Inc. will post -0.1 EPS for the current year.

Analyst Upgrades and Downgrades

ANIK has been the subject of a number of analyst reports. StockNews.com lowered Anika Therapeutics from a "buy" rating to a "hold" rating in a report on Monday. Barrington Research lowered their target price on Anika Therapeutics from $37.00 to $25.00 and set an "outperform" rating for the company in a report on Friday.

Anika Therapeutics Profile

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.